Navigation Links
Celladon Corporation Selected as Winner of Red Herring's "Top 100 North America Tech Startup"
Date:5/29/2013

SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring 's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region.

"We are proud to have been selected as a winner of this award and we are thankful to our devoted employees and investors for their enduring commitment to find a new treatment modality for patients with advanced heart failure." said Krisztina Zsebo Ph.D., President and CEO of Celladon Corporation.  

"In 2013, selecting the Top 100 achievers was by no means a small feat" said Alex Vieux, publisher and CEO of Red Herring . "In fact, we had the toughest time in years because so many entrepreneurs have crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across North America to the Top 100 Winners. We believe Celladon Corporation embodies the vision, drive and innovation that define a successful entrepreneurial venture. Celladon Corporation should be proud of its accomplishment, as the competition was very strong."

Red Herring 's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation and intellectual property, management quality, business model, customer footprint, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the "buzz" and make the list a valuable instrument of discovery and advocacy for the most promising new business models in North America.

About MYDICAR
MYDICAR is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage HF resulting in deficient heart function. With MYDICAR, the SERCA2a gene is delivered using recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR is synergistic and additive across current HF treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician. A recent Phase 2 clinical trial demonstrated sustained improvement at one year in cardiac function parameters and quality of life. A 200 patient Phase 2b study of MYDICAR was initiated in August, 2012

About Celladon
Celladon is a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure and cardiac diseases. The company's lead product, MYDICAR, targets the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon also conducts pre-clinical research on a proprietary platform of small molecule activators of SERCA enzymes for the treatment of metabolic and cardiovascular diseases. Further information can be found at www.celladon.net.


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
5. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
7. Neogen Corporation Announces 2nd Quarter Results Conference Call
8. Luminex Corporation to Present at JP Morgan Healthcare Conference
9. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
10. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical ... Physik Instrumente USA, have been selected as this year’s recipients of two top awards ... have been invited along with other honorees to accept their awards at a banquet ...
(Date:6/22/2017)... ... 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the ... to manage the new site. , Tim has 25 years of pharmaceutical experience, ... role as the Director of Manufacturing and Supplier Quality Assessment. This group ...
(Date:6/22/2017)... ... 22, 2017 , ... For the months of May and ... Spotlight series on “Cell Therapy Regulation” for its regenerative medicine followship. ... unique regulatory challenges of stem cell medical research. , Stem cell clinical trials ...
(Date:6/22/2017)... ... 22, 2017 , ... Charm Sciences, Inc. is pleased to announce that its ... be appropriate as a screening test at dairies and farms for raw commingled cow ... the Charm EZ Lite system. These systems are a combination incubator and reader in ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):